Lonidamine

• Description :

  Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM) . Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis[1][2][3].

• Product Name Alternative :

  AF-1890; Diclondazolic Acid; DICA

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Hexokinase; Mitochondrial Metabolism; Parasite

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Apoptosis; Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/lonidamine.html

• Purity :

  99.91

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3)O

• Molecular Formula :

  C15H10Cl2N2O2

• Molecular Weight :

  321.16

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Nancolas B, et al. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016 Apr 1;473 (7) :929-36. |[2]Ilya A Shutkov, et al. Ru (III) Complexes with Lonidamine-Modified Ligands. Int J Mol Sci. 2021 Dec 15;22 (24) :13468. |[3]Xueqian Yin, et al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-β. Sci Signal. 2019 Dec 17;12 (612) :eaax4067. |[4]Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10 (1) :2205.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [50264-69-2]